Administered intramuscularly or intravenously, and presented in secure glass ampoules, it is perfect for treating peripheral neuropathy, megaloblastic anemia, and B12 deficiency
Assign G90.x codes for non-diabetic autonomic disorders: G90.3 (multi-system atrophy with orthostatic hypotension Shy-Drager), G90.1 (familial dysautonomia/Riley-Day), G90.09 (other idiopathic peripheral autonomic neuropathy)
Test characteristics Species Human Sample types Serum and EDTA plasma Sample volume 25L Assay range 2.7 - 1000 pmol/L Detection limit 1.62 pmol/L Incubation 18-22 h (overnight) + 10 min + 15 min Detection method Chemiluminescence specificity The following cross-reactions have been tested: GIP (1-42) 114-124% GIP (3-42) 100% GIP (1-30) Not detected GIP (3-30) Not detected Glucagon Not detected GLP-1 (9-36) amide Not detected GLP-2 Not detected Oxyntomodulin Not detected Glicentin Not detected Mini-glucagon Not detected Proglucagon 1-61 Not detected MPGF Not detected PACAP-38 Not detected directions for use Certificate of Analysis directions for use Certificate of Analysis SAFETY DATA SHEET references Meessen, E
Julianna Lindsey (07:02.261) love that you bring up that topic because cardiovascular disease is the number one killer of men and it is the number one killer of women
10.1016/j.bbalip.2018.04.005 75
It is important not to freeze the solution, as this can negatively affect the peptides structure and efficacy
![PDF] Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance](https://figures.semanticscholar.org/69d84ad0979bcded8fc643f42a28ce77fbc5b3ff/3-Table2-1.png)
